VJHemOnc Podcast cover image

Novel developments in lower-risk MDS & important practical considerations when treating patients

VJHemOnc Podcast

CHAPTER

Advancements in Low-Risk MDS Treatments

This chapter explores the latest advancements in treatment protocols for low-risk myelodysplastic syndromes (MDS), including the anticipated approval of Emmitalistat. It highlights the importance of supportive collaboration between pharmaceutical companies and cooperative groups to enhance patient care and optimize treatment strategies.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner